October 17, 2016
CTI Clinical Trial & Consulting Services Announces Dr. Elias Anaissie has joined as Medical Director
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ October 17, 2016]
CTI Clinical Trial and Consulting Services (CTI), a multi-national, privately held, full-service contract research organization announces Dr. Elias Anaissie has joined as a Medical Director. Dr. Anaissie is a world-renowned Hematologist/Oncologist with expertise in Infectious Disease research and nearly forty years of experience in clinical research and academia.
“We are excited to have Dr. Anaissie as a part of our team of Medical Directors,” said Lynn Fallon, President. “His internationally-recognized expertise in the treatment of critically ill patients will be a huge asset to the growing team at CTI.”
Prior to joining CTI, Dr. Anaissie served as Director, Program in Hematological Malignancies and Bone Marrow Transplantation at the University of Cincinnati while simultaneously working as an Attending Physician, hematology/oncology at the University of Cincinnati Medical Center. He also has a long tenure as a journal reviewer for various publications, has been an author of 352 peer-reviewed publications, 474 abstracts, 74 textbook chapters, 13 editorials, four U.S. patents, and two textbooks, and is a member of the Society of Hematologic Oncology, the American Society of Hematology, the American Society of Clinical Oncology, and the Infectious Disease Society of America.
Dr. Anaissie earned his MD at the University of Paris XII, Creteil Faculty of Medicine in Paris, France and completed his Internal Medicine Residency Program at Saint Joseph University Medical School in Beirut, Lebanon. Upon completing his residency, Dr. Anaissie studied at the University of Texas MD Anderson Cancer Institute in Houston, TX and developed his Infectious Disease Subspecialty in cancer patients and transplant recipients.
About CTI Clinical Trial and Consulting Services
CTI Clinical Trial and Consulting Services is a global, privately held, full-service contract research organization (CRO), delivering a complete spectrum of clinical trial and consulting services throughout the lifecycle of development, from concept to commercialization. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology, and medical device firms with clinical and disease area expertise in rare diseases, regenerative medicine/gene therapy, immunology, transplantation, nephrology, hematology/oncology, neurology, infectious diseases, hepatology, cardiopulmonary, and pediatric populations. CTI also offers a fully integrated multi-specialty clinical research site that conducts phase I-IV trials. CTI has a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. With clinical trial experience across 6 continents, CTI partners with research sites, patients, and sponsors to fulfill unmet medical needs. CTI is headquartered in Cincinnati, OH, with operations across North America, Europe, Latin America, and Asia-Pacific. For more information visit www.ctifacts.com